In recent years, studies have suggested that high ZFP57 expression is associated with breast cancer, lung cancer, fibrosarcoma, and glioma, which could regulate Wnt/β-Catenin signaling pathway or IGF2, leading to the imbalance of expression of downstream oncogenes such as c-myc or phosphorylated AKT, further influencing the invasion and metastasis of tumor cells 10, 11, 18. This evidence concerns the gene ZFP57 and breast carcinoma.